Oncology1 year ago
In a Phase 2 trial, Lixisenatide as adjunct therapy for early Parkinson’s disease showed promise.
The findings from the phase 2 LixiPark trial (NCT03439943), which were presented at the 2023 International Congress of Parkinson’s Disease and Movement Disorders, held August 27-31...
